The difference between Ustekinumab 130mg and 90mg

Ustekinumab is a biologic agent indicated for the treatment of plaque psoriasis in adults and children at least 6 years of age, psoriatic arthritis in adults, sometimes in combination with methotrexate, active psoriatic arthritis in children at least 6 years of age, moderate to severe Crohn's disease in adults after other drugs have failed, and moderate to severe ulcerative colitis in adults. Ustekinumab is available in two common dosage forms: 130 mg, 45 mg, and 90 mg.

Ustekinumabis a humanIgG1κ monoclonal antibody and a human interleukin-12 and -23 antagonist. Ustekinumab for subcutaneous injection is supplied as 0.5 mL of 45 mg ustekinumab and 1 mL of 90 mg ustekinumab as sterile solutions in single-dose prefilled syringes with 27-gauge fixed-inch needles. Intravenous ustekinumab is available as 26mL of 130mg of ustekinumab in a single-dose 30mL Type I glass vial with a coated stopper.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.